Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System ( CLN3SS )
JIMD Reports · 2026-11 · 67 (6)
DOI: 10.1002/jmd2.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 05.11.2026. Verfasst von Samuel D Moran und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester School of Medicine and Dentistry Rochester New York USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health, Batten Disease Support and Research Association.
Abstract (Originalsprache)
CLN3 disease is an inherited neurodegenerative disease, typically with childhood onset, and characterized by vision loss, seizures, cognitive decline, and difficulties. The CLN3 Staging System (CLN3SS) characterizes disease progression. Our aim was to assess differences in cognitive test scores in relation to CLN3SS among individuals with CLN3 disease. We evaluated the relationship between cognitive test performance and the CLN3SS in individuals with genetically confirmed CLN3 disease. Participants completed tasks of verbal reasoning, vocabulary knowledge, attention, fund of information, and ability to recite the alphabet. One‐way ANOVA testing assessed differences in mean cognitive test score among CLN3SS score groups, and chi‐square testing was used to compare the proportion in each CLN3SS group that could recite the alphabet. Data were evaluated from a sample of 85 individuals with a total 245 CLN3SS assessments conducted within 6 months of their cognitive testing, A significant decrease in test scores was found between CLN3SS Stages 1 (vision loss present) and 2 (vision loss and seizures present) for each of the cognitive tests. The proportion of participants able to recite the alphabet also decreased from Stage 1 to Stage 2 ( χ 2 = 12.1, p < 0.01). Cognitive ability declines with advanced disease severity in CLN3 disease, though motor disability in Stage 3 likely contributes to difficulty participating in cognitive assessment at this later disease stage. Understanding the relationship between cognition and CLN3 disease stage may help guide decision making, that is, determining who could or should undergo cognitive assessment for clinical care or for group stratification in disease modifying clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Rochester School of Medicine and Dentistry Rochester New York USA.
- Kennedy Krieger Institute Baltimore Maryland USA.
- Department of Neurology University of Rochester Medicine Rochester New York USA.
- Independent Consultant Pittsford New York USA.
ORCID-Profile: Samuel D Moran, Erika F Augustine, Jonathan W Mink, Marianna Pereira-Freitas, Jennifer Vermilion, Amy E Vierhile, Heather R Adams
Förderung
- NINDS NIH HHS
- National Institutes of Health
- Batten Disease Support and Research Association
Zitieren
APA
Moran, S. D., Augustine, E. F., Mink, J. W., Pereira-Freitas, M., Taggart, N. S., Vermilion, J., Vierhile, A. E., & Adams, H. R. (2026). Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System ( CLN3SS ). JIMD Reports, 67(6). https://doi.org/10.1002/jmd2.70136
Vancouver
Moran SD, Augustine EF, Mink JW, Pereira-Freitas M, Taggart NS, Vermilion J, et al. Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System ( CLN3SS ). JIMD Reports. 2026;67(6). doi:10.1002/jmd2.70136
BibTeX
@article{Moran2026,
author = {Moran, Samuel D and Augustine, Erika F and Mink, Jonathan W and Pereira-Freitas, Marianna and Taggart, Naomi S and Vermilion, Jennifer and Vierhile, Amy E and Adams, Heather R},
title = {Cognitive Test Performance in CLN3 Disease Is Associated With the CLN3 Staging System ( CLN3SS )},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {6},
doi = {10.1002/jmd2.70136}
}
EUVIMED